Junko Yanagawa
YOU?
Author Swipe
View article: NF9 peptide specific cytotoxic T lymphocyte clone cross react to Y453F mutation of SARS-CoV-2 virus spike protein
NF9 peptide specific cytotoxic T lymphocyte clone cross react to Y453F mutation of SARS-CoV-2 virus spike protein Open
The recognition by cytotoxic T cells (CTLs) is essential for the clearance of SARS-CoV-2 virus-infected cells. Several viral proteins have been described to be recognized by CTLs. Among them, the spike (S) protein is one of the immunogenic…
View article: Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma Open
Bladder cancer is a major and fatal urological disease. Cisplatin is a key drug for the treatment of bladder cancer, especially in muscle-invasive cases. In most cases of bladder cancer, cisplatin is effective; however, resistance to cispl…
View article: Cisplatin‐induced <scp>HSF1‐HSP90</scp> axis enhances the expression of functional <scp>PD‐L1</scp> in oral squamous cell carcinoma
Cisplatin‐induced <span>HSF1‐HSP90</span> axis enhances the expression of functional <span>PD‐L1</span> in oral squamous cell carcinoma Open
Immune checkpoint inhibitor‐based cancer immunotherapy has provided an additional therapeutic option for oral squamous cell carcinoma (OSCC) with recurrence or distant metastases. However, further improvement of OSCC treatment is required …